More Than Just Risk: Genetic Testing Is Shaping Breast Cancer Treatment

https://myriad.com/.../what-does-rna-analysis-actually-add-to-hereditary-ca...

What Does RNA Analysis Actually Add to Hereditary Cancer Testing?

Jul 7, 2025 ... Myriad's BRCA1 and BRCA2 VUS rates are just 0.30% and 0.70%, respectively.¹ That means more patients receive clear, actionable results the ...

https://investor.myriad.com/news-releases/news-release-detail/12241/

Myriad Will Seek Japanese Regulatory Approval for BRACAnalysis ...

Nov 7, 2016 ... ... BRCA1 and BRCA2 genes using genomic DNA obtained from whole blood specimens. It is approved for use as a companion diagnostic with ...

https://investor.myriad.com/news-releases/news-release-detail/12326/

Myriad Genetics and BeiGene Sign Agreement to Develop ...

Apr 6, 2017 ... ... BRCA1 and BRCA2 genes using genomic DNA obtained from whole blood specimens. About myChoice^® HRD Myriad's myChoice HRD is the first ...

https://myriad.com/.../understanding-the-risks-raising-awareness-about-ovar...

Understanding the Risks: Raising Awareness about Ovarian Cancer

Sep 12, 2023 ... ... BRCA1 or BRCA2, or one associated with Lynch syndrome.” According to the CDC website, other risk factors may include if you: Are middle-aged ...

https://investor.myriad.com/news-releases/news-release-detail/11036/

Myriad Genetics Acquires Exclusive Rights to RAD51C Gene

Today, the majority of hereditary breast and ovarian cancer is thought to be due to an alteration or gene mutation in either the BRCA1 or BRCA2 genes. A ...

https://investor.myriad.com/news-releases/news-release-detail/20741/

FDA Approves Myriad's myChoice® CDx Test to Help Identify ...

myChoice CDx is the first and only tumor test that determines homologous recombination deficiency status by detecting BRCA1 and BRCA2 (sequencing and large ...

https://investor.myriad.com/news-releases/news-release-detail/12016/

Myriad Advances Proprietary myVision® Variant Classification Tools ...

Mar 8, 2016 ... In this study, the Pheno algorithm was used to analyze variants of unknown significance associated with high cancer risk genes including BRCA1, ...

https://investor.myriad.com/news-releases/news-release-detail/20921/

Myriad's Polygenic Risk Score Personalizes Risk of Breast Cancer ...

This validation study evaluated the 86-SNP PRS as a breast cancer risk factor for women who carry PV in the BRCA1, BRCA2, CHEK2, ATM and PALB2 genes and for ...

https://investor.myriad.com/news-releases/news-release-detail/25201/

QIAGEN and Myriad Genetics develop distributable homologous ...

MyChoice CDx assesses the HRD status by examining a tumor's DNA repair capabilities, particularly focusing on BRCA1 and BRCA2 gene mutations and calculating a ...

https://investor.myriad.com/news-releases/news-release-detail/25296/

Myriad Genetics Collaborates with GSK to Improve Access to HRD ...

Jun 11, 2024 ... ... BRCA1 and BRCA2 and Genomic Instability Score (GIS) status using Myriad's proprietary algorithm. It enables healthcare professionals to ...